Cargando…

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)

Detalles Bibliográficos
Autores principales:	Agraz-Pamplona, I., Larrosa-Garcia, M., Bury-Macias, R. P., Serón-Micas, D., Montoro-Ronsano, J. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481148/ https://www.ncbi.nlm.nih.gov/pubmed/32514744 http://dx.doi.org/10.1007/s00228-020-02906-z

Ejemplares similares

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2023)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
por: Sans-Atxer, Laia, et al.
Publicado: (2013)

Cellular abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) fibroblasts
por: Moyes, S, et al.
Publicado: (2012)

Echocardiographic Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients
por: Pfeferman, Mariana Becker, et al.
Publicado: (2022)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
por: Pellegrino, Angela Maria, et al.
Publicado: (2019)

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017)

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021)

Informatics-guided drug repurposing for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Kiseleva, Anna A., et al.
Publicado: (2020)

Systems biology approaches toward autosomal dominant polycystic kidney disease (ADPKD)
por: Rahimmanesh, Ilnaz, et al.
Publicado: (2020)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model
por: McEwan, Phil, et al.
Publicado: (2018)

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020)

Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges
por: McBride, Lucy, et al.
Publicado: (2020)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
por: Kunizawa, Kyohei, et al.
Publicado: (2018)

Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Iijima, Hiroko, et al.
Publicado: (2022)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023)

Recurrent Cholangitis in a Patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Caroli's Disease
por: Hasegawa, Eiko, et al.
Publicado: (2016)

Association of Vitamin D Levels With Kidney Volume in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Vendramini, Larissa Collis, et al.
Publicado: (2019)

Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
por: Zubidat, Dalia, et al.
Publicado: (2023)

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants
por: Harris, Tess, et al.
Publicado: (2018)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2020)

Bilineal inheritance of type 1 autosomal dominant polycystic kidney disease (ADPKD) and recurrent fetal loss
por: Peces, Ramón, et al.
Publicado: (2008)

Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Maxeiner, Andreas, et al.
Publicado: (2019)

Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Sekine, Akinari, et al.
Publicado: (2022)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

Autosomal dominant polycystic kidney disease in young adults
por: Martínez, Víctor, et al.
Publicado: (2022)

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience
por: Guerra-Torres, Xavier E, et al.
Publicado: (2020)

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
por: Moriyama, Tomofumi, et al.
Publicado: (2020)

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Naranjo, Javier, et al.
Publicado: (2022)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_28s1b9hak2anec049vvmv17651